Can LeMaitre Vascular (LMAT) Stock Reach $110?

Key Takeaways

• The $110 central target is the rounded arithmetic mean of the most recent, individually attributed analyst price targets for LeMaitre Vascular, Inc. (LMAT), a medical-device and vascular-tissue company.
• With the stock near $82.31, reaching $110 would require a rise of roughly 34%, a substantial move.
• Current targets span a wide range of about $81 to $135, reflecting a genuine split between cautious and bullish analysts.
• Key supports include double-digit organic revenue growth, margin expansion, and a global distribution buildout.
• Principal risks are a recent earnings miss, a leadership transition, premium valuation, and tissue-supply constraints.

Analyst Price Targets and Consensus View

LeMaitre Vascular is covered by roughly eight to nine sell-side analysts, and their views are unusually divided. The arithmetic mean of the most recent attributed targets is approximately $110, consistent with aggregator figures of about $107 (S&P Global, eight analysts) to $110.60 (MarketBeat, nine analysts). This article uses a rounded $110 central target.

The range is wide. On the cautious side, Freedom Capital Markets cut its target to $81 (Hold) in August 2026, and Wells Fargo lowered its target to $94 (Equal-Weight) the same month. On the bullish side, Stifel Nicolaus holds a $120 Buy target, Citizens JMP a $127 Market Outperform, Sidoti a $132 Buy, and Lake Street a $135 Buy. Roth MKM sits in between at $117 (Buy).

Sentiment has cooled sharply from the spring. After a May 2026 wave of target increases, several firms turned more defensive: Zacks Research downgraded the stock to Hold in July, Barrington Research moved to Market Perform in August, and Freedom Capital Markets and Wells Fargo cut their targets after the company's August 4 quarterly report missed consensus. The net result is a "Hold"-to-"Buy" mix with no Sell ratings, but with materially lower price expectations than earlier in the year.

Current Market Position and Path Toward the Target

At a recent close of $82.31, LMAT sits near the bottom of its 52-week range of $78.22 to $118.01 and below its 200-day moving average of roughly $94. Reaching $110 implies a gain of about 34%, which is substantial rather than modest, and would mean retracing most of the decline from the stock's 52-week high.

The company reported second-quarter EPS (earnings per share) of $0.74, below the $0.81 consensus, on revenue of $70.38 million versus the $71.47 million expected, though revenue still rose 9.6% year over year. Management's full-year 2026 guidance calls for sales of roughly $274 million to $278 million and EPS of $2.84 to $2.94. The stock trades at about 28.9 times trailing earnings, a premium to the broader medical-device group.

What Could Support a Move Toward the Target

• Consistent organic growth. LeMaitre has posted double-digit annual revenue growth, driven by products such as Artegraft and cardiac allografts used in vascular and cardiac procedures.
• Margin expansion. A buildout of direct-to-hospital distribution and new warehouses in markets including Billerica, Madrid, Paris, Toronto, and Warsaw is aimed at lowering shipping costs and lifting gross margin.
• Global expansion. Artegraft is approved in dozens of countries, with launches planned in additional markets, extending a runway beyond the U.S. base.
• Financial strength. A cash balance near $376 million, a modest payout ratio, and a $1.00 annual dividend (about a 1.2% yield) give the company flexibility to fund growth.
• Favorable demographics. An aging population and rising procedure volumes underpin long-term demand for vascular-surgery devices.

What Could Prevent the Target From Being Reached

• Execution misses. The second-quarter shortfall against guidance and consensus shook confidence, and further misses could compress the valuation.
• Leadership transition. President David B. Roberts notified the company in October 2026 of plans to retire at year-end, adding uncertainty during a demanding expansion phase.
• Supply constraints. Chronic tissue-supply limits in radiofrequency ablation (RFA) and cardiac allografts, plus a processing relocation to Burlington, could cap volume growth.
• Valuation risk. At roughly 29 times trailing EPS, the stock carries a premium multiple that leaves little room for error.
• External headwinds. Foreign-exchange pressure and Middle East export disruptions could temper international momentum.

Technical Levels and Market Structure

LMAT is trading near its 52-week low of $78.22, which now acts as a key support level, with the 50-day moving average near $81 providing nearby reference. The 200-day moving average around $94 represents the first significant resistance zone, followed by the psychologically important $100 level. A move toward $110 would require clearing both, essentially rebuilding the uptrend that stalled after the stock peaked near $118 earlier in the year.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts apply different assumptions about growth, margins, and the appropriate multiple. The next earnings report, scheduled for early November 2026, is the most important near-term event, along with any guidance updates, tissue-supply commentary, and progress on the international warehouse buildout. Investors should also watch for further analyst revisions, the handling of the leadership transition, and any change in the valuation multiple.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a name like LeMaitre Vascular, which sits near a technical support level with a divided analyst community, such signals can help traders spot changing trends, monitor positions, and discover opportunities more efficiently. Explore the AI Daily Buy/Sell Signals to see how automated analysis frames LMAT's current setup.

Final Assessment

The $110 central target is not a guarantee but an average of current analyst expectations, requiring a substantial gain of roughly 34% from the stock's recent price near $82. The bull case rests on durable organic growth, margin expansion, and global reach, while the bear case emphasizes the recent earnings miss, the leadership transition, supply constraints, and a premium valuation. The unusually wide $81-to-$135 analyst range signals real disagreement about whether execution and valuation concerns are temporary or structural. The upcoming earnings report and guidance will likely be decisive in determining whether the path toward $110 opens or remains blocked.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations